close

Agreements

Date: 2011-06-02

Type of information: R&D agreement

Compound: small molecule modulators of a priority biological target

Company: Evotec (Germany) Active Biotech (Sweden)

Therapeutic area: Immune diseases - Cancer

Type agreement:

R&D

Action mechanism:

Disease:

Details:

Evotec AG has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Based on excellent progress made using its state-of-the-art Screening Platform in 2010, Evotec will now apply its integrated medicinal chemistry platform to optimise initial screening hits with the aim of progressing into a lead optimisation programme.

Financial terms:

Financial details were not disclosed.

Latest news:

Is general: Yes